30 news items
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
BMY
13 Jun 24
materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, whether
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
BMY
4 Jun 24
be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
BMY
3 Jun 24
, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
BMY
1 Jun 24
be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied
U.S. Food and Drug Administration Approves Bristol Myers Squibb's Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
BMY
30 May 24
our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks
xg2bhiawrwt2k172yrr1iot3i6
BMY
CCCC
ONCY
28 May 24
will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved
jp9wy9b 466ow9782tls46lfr9lg2musixzqgmt60s1fz9qiam
BMY
CCCC
ONCY
28 May 24
will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics
cxl5tiwqdq3l9ulqke uimxupnes643909rb6ff1yh
BMY
23 May 24
materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others
5cg rg4dg36mcb0knz
BMY
16 May 24
and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include
yjqcp3aj7
BMY
15 May 24
cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks
zb0kteewxijm6l3swjehdhtrdhknobq5j26m530xw854jfp3z8n0doovc80
BMY
10 May 24
results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties
l4g8jz 7l5rhscxz8lytan
AAL
AAPL
ABBV
29 Apr 24
. On the other hand, healthcare, energy, and materials have reported year-over-year earnings declines.
See Also
xoq6h4jpiqsp9mqq97fdyicdliarm9lks60qn7xbs1b
BMY
26 Apr 24
and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements
3t21wx4 tilt
BMY
CVX
META
26 Apr 24
, health care and real estate stocks recording the biggest losses on Thursday. However, materials and emergy stocks bucked the overall market trend
8fojqazijp62op1hf8eor9heb2t0ylk6vtns1572vib3 qbyep5go8do87
BMY
25 Apr 24
be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. See